Novel artificial cell microencapsulation of probucol and bile acids in diabetes mellitus
Access Status
Open access
Authors
Mooranian, Armin
Date
2018Supervisor
Dr Hani Al-Salami
Type
Thesis
Award
PhD
Metadata
Show full item recordFaculty
Health Sciences
School
Pharmacy
Collection
Abstract
This thesis studied bile acids in the oral delivery of the anti-diabetic compound probucol as therapy for diabetes mellitus and in the application of microencapsulation of pancreatic β- cells. Bile acids improved the stability of the pharmaceutical formulation system containing probucol and enhanced the oral delivery resulting in greater bioavailability, tissue concentrations and glucose lowering effects in diabetic animals. Bile acids also improved the viability and activity of pancreatic β-cells within microcapsules via cellular protective effects.
Related items
Showing items related by title, author, creator and subject.
-
Mooranian, Armin; Zamani, Nassim; Takechi, Ryu; Al-Sallami, H.; Mikov, M.; Golocorbin-Kon, S.; Kovacevic, B.; Arfuso, Frank; Al-Salami, Hani (2018)INTRODUCTION: The ratio of secondary to primary bile acids changes during Type 1 Diabetes (T1D) development and these effects might be ameliorated by using cholesterol lowering drugs or hydrophilic bile acids. Probucol ...
-
Mathavan, Sangeetha; Chen-Tan, N.; Arfuso, Frank; Al-Salami, Hani (2015)Context: Gliclazide (G) is a commonly prescribed drug for Type 2 diabetes (T2D). In a recent study, we found that when G was combined with a primary bile acid, and gavaged to an animal model of Type 1 diabetes (T1D), it ...
-
Woodhams, L.; Al-Salami, Hani (2017)Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by the loss of glycemic control. Recent studies have shown significant inflammation and disturbed bile acid homeostasis, associated with T1DM. Bile ...